 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling...

Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Down 49.4% in March

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023

Tenax Therapeutics GAAP EPS of -$31.04...

Tenax Therapeutics GAAP EPS of -$31.04

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction...

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics: Q4 Earnings Insights

CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart...

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Tenax Therapeutics (NASDAQ:TENX  Get Free Report)s stock had its buy rating reiterated by equities researchers at Roth Mkm in a research report issued to clients and...

Tenax Therapeutics (NASDAQ:TENX) Stock Rating Reaffirmed by Roth Mkm

Amendment to existing exclusive license agreement with Orion Corporation expands Tenax's territory rights from North America, to the entire worldExpanded rights position Tenax to engage potential...

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Tenax Therapeutics, Inc. (NASDAQ:TENX  Free Report)  Analysts at Zacks Small Cap increased their FY2023 earnings estimates for Tenax Therapeutics in a research note issued on Monday...

Tenax Therapeutics, Inc. to Post FY2023 Earnings of ($31.05) Per Share, Zacks Small Cap Forecasts (NASDAQ:TENX)

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Volume (M)	13,788.00
52-Wk High	$61.20
52-Wk Low	$3.48

TENX Tenax Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals